Given that sotigalimab upregulated PD-L1 in the TME, the dual targeting of PD-1 or PD-L1 and CD40 with neoadjuvant chemoradiation in E/GEJ cancer is a rational strategy for future trials. Here, CD40 is linked to cancer.